|
|
Volumn 1 Suppl 1, Issue , 2000, Pages
|
|
Antiaromatase agents after adjuvant tamoxifen: rationale and clinical implications.
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;
AROMATASE INHIBITOR;
TAMOXIFEN;
ADJUVANT CHEMOTHERAPY;
BREAST TUMOR;
CLINICAL TRIAL;
DRUG ADMINISTRATION;
DRUG RESISTANCE;
FEMALE;
HUMAN;
REVIEW;
RISK FACTOR;
ANTINEOPLASTIC AGENTS, HORMONAL;
AROMATASE INHIBITORS;
BREAST NEOPLASMS;
CHEMOTHERAPY, ADJUVANT;
CLINICAL TRIALS;
DRUG ADMINISTRATION SCHEDULE;
DRUG RESISTANCE, NEOPLASM;
FEMALE;
HUMANS;
RISK FACTORS;
TAMOXIFEN;
MLCS;
MLOWN;
|
|
EID: 4444272276
PISSN: 15268209
EISSN: None
Source Type: Journal
DOI: 10.3816/cbc.2000.s.005 Document Type: Review |
|
Times cited : (2)
|
|
References (51)
|
